CN Menu
News
News
Release Date
All 2023 2022 2021 2020 2019
Nov, 2021
10
Shenzhen Evergreen Pharmaceutical Co., Ltd. established Hetao Laboratory
Since the first Hetao International Pharmaceutical Forum was successfully held on May 13, 2021, Dr. Du Tao, chairman of Shenzhen Evergreen Pharmaceutics Co., LTD. (hereinafter referred to as "Evergreen Pharmaceutics"), as the initiator of the forum, has been paying close attention to the development of Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Hetao as shenzhen and Hong Kong "bite" is extremely conducive to Chinese enterprises and international docking. At the same time, the drug audit center will be located here in the future to facilitate the development of innovative pharmaceutical research and development enterprises. Therefore, Dr. Du Tao believes that Evergreen, which has strong ability of drug innovation and development, should enter
Mar, 2021
15
Evergreen Therapeutics, Inc. Raised RMB 100 million in Series A Financing to Develop Covid-19 Drugs
On March 15, a fast-growing bio-innovative pharmaceutical company, Evergreen Therapeutics, announced the completion of RMB 100 million Series A financing. This round of financing was led by Shenzhen Tiantu Capital, Shenzhen Share Capital, and other investment institutions followed. The funds raised will be used to support Evergreen's new drug research and development, including phase II clinical trial of coronavirus pneumonia injection drug EG-009A and the development of other clinical phases and preclinical projects.  "Evergreen Therapeutical, Inc. received three US FDA clinical approvals in just over a year. Its success is a result of Evergreen’s professional and excellent team, and is also inseparable from the trust and support of investors." Dr. Du Tao, Chairman of Evergr
Apr, 2020
05
Evergreen Therapeutics, Inc. Announced to Develop EG-009 for the Treatment of Moderate to Severe COVID-19
In April 2020, Evergreen Therapeutics, Inc. announced the development of a new pipeline, EG-009, to treat the Cytokine Release Syndrome (CRS) caused by the Novel Coronavirus pneumonia. Epidemiologists predict that the world will remain in a pandemic state until June 2021. The virus continues to spread at a slow rate, and intermittent lockdowns are the new normal. It is estimated that 250 million people worldwide will be infected and 1.75 million will die by June 2021.CRS is one of the leading causes of death in COVID-19 patients. CRS is a complex inflammatory response. During the occurrence of CRS, various cytokines such as TNF-, IL-1, IL-6, IL-12, IFN-, IFN-, McP-1, and IL-8 are produced in large quantities in body fluids. CRS can cause acute respiratory distress syndrome and mu
Oct, 2021
18
The First Offline Meeting of Evergreen USA Team was Held to Review Achievements and Look into the Future
On October 18-19, 2021, Evergreen Therapeutics Co., Ltd. held its first offline meeting at the US headquarters since the outbreak in Bethesda, Maryland. Dr. Du Tao, Chairman of the Board, Dr. Du Xin, Chief Executive Officer, Dr. Li Changqing, Chief Medical Officer, COO Kevin Wang, CFO Julia Lu, Clinical and preclinical Division Director, senior consultant of the company and former senior FDA officer Dr. Florence Houn and other members of Evergreen's consulting team attended the meeting. Figure 1: The first meeting of Evergreen's team, department directors and consultantsUnder the chairmanship of Dr. Du Xin, the meeting reviewed the excellent achievements of Evergreen pharmaceutical in the past two years; Dr. Li Changqing, chief Medical Officer, made a systematic
Oct, 2021
16
FDA Experts Association Holds Autumn Gathering in Washington DC
In celebration of “Golden Autumn”, on October 16, 2021, the FDA Experts Association held the North America Golden Autumn Party at Han Palace in North Bethesda, Maryland. Since its establishment in 2019 on the bank of West Lake in Hangzhou, China, the association has grown stronger under the leadership of its presidents (first President, He Ruyi; current President, Du Tao; President-elect, Li Ning) to become a group of nearly 100 people. Members reside throughout China and the United States, with new members continuously joining, including Liu Ke (Senior VP and Director of Regulatory Affairs & Strategy at Sana Biotechnology) and Wang Yaning (CEO of Createrna Science & Technology). New members have brought fresh
Oct, 2021
14
Urgent Breakthrough Needed for the Treatment of Covid-19, Evergreen Offers New Anti-Inflammatory Treatment Approach
During China’s October National Day, news of Merck’s investigational oral pill (Molnupiravir) for treating Covid-19 was received with great excitement and many questions: is a special drug finally born? Will the treatment of Covid-19 be similar to that for the common cold? Will the new drug become the panacea in ending the Covid-19 pandemic? However, shortly thereafter, reports from India indicated that the drug has “no significant efficacy” for patients with moderate Covid-19 symptoms, making it difficult at this time to determine the efficacy of Molnupiravir for treating Covid-19. We at Evergreen are not surprised; as we understand it, according to the 10 technical pathways of vaccine development and 10 EUA products approved by the FDA, every aspect of the fight against SARS-CoV-2 h
Oct, 2021
13
Evergreen CMC Team Visits Partnership (Pii) Manufacturing Facility, to Conduct Quality Control Inspection for the Production of Anti-Coronavirus Drug
Bethesda, Maryland – October 4, 2021 – Evergreen Therapeutics announces that the CMC team, led by Evergreen CEO, Dr. Xin Du, visited its US partner, Pharmaceutics International, Inc. (Pii), and met with the project team to discuss the production of the new anti-coronavirus drug.  Dr. Du and his team visits Pii facility During the meeting, Pii’s project leader introduced and explained the company's production site via video, during which Evergreen’s CMC team discussed possible issues and solutions regarding drug production with each of Pii’s production-line teams. Thereafter, the Evergreen CMC team, guided by Pii team members, also visited several facilities, including the cGMP manufacturing area, the formulation R&D lab, and the cGMP warehouse. Evergr
Sep, 2021
30
What is the secret of Evergreen Therapeutics? Only two years after the Company’s founding, it is directly challenging current "standard of care” treatments for advanced endometrial cancer
Dr.Charles Lee, CMO of EvergreenDr. Li Changqing, CMO of Evergreen Therapeutics (“Evergreen” or the “Company”) shared his excitement on the very intuitive demonstration of the efficacy of the EG-007 combination: “Simply comparing the size of tumor residual in the same animal trial, the average tumor weight after dual-drug treatment was approximately 730 mg, while after our three-drug regimen it was just over 300 mg.”EG-007 was the first drug candidate Dr. Li led after joining Evergreen. In mid-July this year, Dr. Li assumed position of Evergreen CMO. Subsequently in August, after two pre-IND meetings, the FDA approved the Phase III pivotal clinical trial protocol of EG-007 in combination with targeted drugs and anti-PD-1 antibody analogs for the treatment of advanced endometrial cancer. No
Sep, 2021
14
Shenzhen Evergreen Therapeutics' COVID-19 Drug EG-009A has been approved for phase II clinical trials in India
Evergreen Therapeutics Inc. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") announced on September 14, 2021 that DCGI, the Indian regulatory authority, has officially approved the phase II clinical trial of EG-009A for COVID-19 in India.EG-009A is one of Evergreen's 13 R&D pipelines and will be used to treat Cytokine Release Syndrome (CRS) caused by COVID-19 infections. India is one of the major regions where the Delta variant of COVID-19 is prevalent, and the phase II clinical trial was approved to understand the efficacy of EG-009A in patients with moderate to severe COVID-19 caused by the Delta variant. It is understood that this is the world's first clinical trial with COVID-19 Delta variant as the main research target, so it has a great clinical significan
Aug, 2021
10
The U.S. Food and Drug Administration (FDA) Has Approved Evergreen's EG-007 for Phase III Pivotal Clinical Trial
On August 10, 2021, Shenzhen Evergreen Pharmaceutical Co., Ltd. announced that its innovative drug candidate EG-007 has been approved by the U.S. Food and Drug Administration (FDA) to conduct a phase III pivotal clinical trial in combination with targeted drugs and anti-PD-1 antibody drugs for the treatment of advanced endometrial cancer. The primary objective of this clinical trial is to improve the therapeutic effect/response rate to immunotherapy in patients with advanced endometrial cancer by combining EG-007. The results of this phase III clinical trial will serve as a pivotal trial to provide sufficient evidence for EG-007 to receive global regulatory marketing filing (NDA) approval.  FDA approved EG-007 for phase III clinical trials in patients with advanced endometrial ca
page.total 21 page.tiao page.pre page 123 page.next page page.go/ispage.page